Key result
Adding proton pump inhibitors to dual antiplatelet therapy after PCI reduces gastrointestinal bleeding and events without affecting major cardiovascular events, death, recurrent MI, stent thrombosis, or stroke.
Why the study?
Does adding proton pump inhibitors to dual antiplatelet therapy reduce gastrointestinal bleeding without increasing cardiovascular events in patients after percutaneous coronary intervention?
Does adding proton pump inhibitors to dual antiplatelet therapy reduce gastrointestinal bleeding without increasing cardiovascular events in patients after percutaneous coronary intervention?
Adding a proton pump inhibitor to dual antiplatelet therapy after PCI reduces gastrointestinal bleeding without increasing the risk of adverse cardiovascular events.
Answers are grounded in this paper and cite their sources.
Supports PPI co-prescription with DAPT post-PCI to cut GI risk; confirms ischemic safety in Level 1 synthesis.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Q et al. (2019) studied this question. Adding proton pump inhibitors to dual antiplatelet therapy after PCI reduces gastrointestinal bleeding and events without affecting major cardiovascular events, death, recurrent MI, stent thrombosis, or stroke.
Synapse has enriched 10 related papers. Consider them for comparative context: